Eledon Pharmaceuticals (ELDN) Total Non-Current Liabilities (2015 - 2026)

Eledon Pharmaceuticals has reported Total Non-Current Liabilities for 12 years, with the latest figure at $15.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 32.78% year-over-year to $15.8 million; the trailing twelve-month figure through Mar 2026 stood at $15.8 million (up 32.78% YoY), and the FY2025 full-year result was $20.8 million, up 44.54% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $15.8 million, down from $20.8 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $20.8 million in Q4 2025, with the low at $4.7 million in Q3 2023.
• Historically, Total Non-Current Liabilities has averaged $11.6 million across 5 years, with a median of $11.9 million in 2025.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities tumbled 34.41% — and 2024, when it soared 207.48%.
• Eledon Pharmaceuticals' Total Non-Current Liabilities stood at $8.6 million in 2022, then plunged by 34.41% to $5.6 million in 2023, then jumped by 155.0% to $14.4 million in 2024, then surged by 44.54% to $20.8 million in 2025, then retreated by 23.94% to $15.8 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $15.8 million (Q1 2026), $20.8 million (Q4 2025), and $16.9 million (Q3 2025), per Business Quant data.